Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2026-02-11 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement of the outcome of a board meeting held on 11.02.2026, which includes the approval of unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2025. It contains the full unaudited financial statements, notes, and an independent auditor's review report. The presence of comprehensive financial data, including income, expenses, profit, tax, and other comprehensive income, as well as auditor's review, indicates this is a substantive interim financial report. The document references compliance with SEBI Listing Regulations and Indian Accounting Standards for interim financial reporting (Ind AS 34). It is not merely an announcement or a certification but contains the actual financial results and analysis for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2026
2026-02-11 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement of the outcome of a Board Meeting held on 11.02.2026 by ZIM Laboratories Limited. It includes the approval and disclosure of unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2025. The document contains the full unaudited financial statements with detailed income, expenses, profit, tax, and comprehensive income data. It also includes the Independent Auditor's Review Report on these interim financial results, referencing Indian Accounting Standard 34 (Ind AS 34) for interim financial reporting. The presence of detailed financial data for a period shorter than a full fiscal year, along with auditor review, confirms this is an Interim / Quarterly Report. The document is not merely an announcement or a certification but contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2026
2026-02-11 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the submission of a notice published in newspapers about a Special Window for Re-Lodgement of Transfer Requests of Physical Shares. It references compliance with SEBI regulations and a SEBI circular. The content is an announcement of a notice published in newspapers, not the notice itself or a detailed report. The document is about informing the exchanges about the publication of this notice for shareholders. It does not contain financial statements, management discussion, or detailed report data. The document length is 15,000 characters, but the content is primarily an announcement of a notice publication, not the report or notice itself. Therefore, according to the MENU VS MEAL rule, this is a Report Publication Announcement (RPA).
2026-02-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification dated 06.02.2026 from ZIM Laboratories Limited addressed to stock exchanges about the scheduling of an earnings conference call for Q3 & 9MFY26. It includes details about the call timing, participants, and dial-in information. There is no actual financial data or results disclosed in this document; it is purely an announcement of the upcoming earnings call event. According to the classification rules, announcements about conference calls are classified as Call Transcript (CT) only if they contain the full transcript. Since this document only announces the call and provides logistics, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other categories better. The document length is short (2917 characters), and it does not contain financial statements or detailed financial analysis, so it is not an Interim Report or Earnings Release. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-02-06 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-02-05 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges and compliance departments, dated February 5, 2026. It informs about a scheduled Board of Directors meeting on February 11, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025. It also mentions the closure of the trading window as per insider trading regulations. The document is an announcement of an upcoming board meeting and financial results approval, not the financial results report itself. The length is short (2347 characters), and it does not contain any financial data or detailed analysis. Therefore, it is an announcement related to board/management information, specifically about a board meeting and financial results approval. This fits best under Board/Management Information (MANG).
2026-02-05 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.